The association between sodium/glucose cotransporter-2 inhibitors and adverse clinical events in patients with chronic kidney disease: a systematic review and meta-analysis of randomised controlled trials

References

• Heerspink HJL, Stefansson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney disease. N Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816.
   PubMed Web of Science ®Google Scholar
• Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744.
   PubMed Web of Science ®Google Scholar
• Li N, Zhou GW, Zheng YW, et al. Effects of SGLT2 inhibitors on cardiovascular outcomes in patients with stage 3/4 CKD: a meta-analysis. PLOS One. 2022;17(1):e0261986. doi: 10.1371/journal.pone.0261986.
   PubMed Web of Science ®Google Scholar
• House AA. Management of heart failure in advancing CKD: core curriculum 2018. Am J Kidney Dis. 2018;72(2):284–295. doi: 10.1053/j.ajkd.2017.12.006.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening heart failure. N Engl J Med. 2021;384(2):117–128. doi: 10.1056/NEJMoa2030183.
   PubMed Web of Science ®Google Scholar
• Verma S, Bhatt DL. More CREDENCE for SGLT2 inhibition. Circulation. 2019;140(18):1448–1450. doi: 10.1161/CIRCULATIONAHA.119.041181.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Verma S, Braunwald E. The DAPA-HF trial: a momentous victory in the war against heart failure. Cell Metab. 2019;30(5):847–849. doi: 10.1016/j.cmet.2019.10.008.
   PubMed Web of Science ®Google Scholar
• Connelly KA, Bhatt DL, Verma S. Can we DECLARE a victory against cardio-renal disease in diabetes? Cell Metab. 2018;28(6):813–815. doi: 10.1016/j.cmet.2018.11.010.
   PubMed Web of Science ®Google Scholar
• Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–357. doi: 10.1056/NEJMoa1812389.
   PubMed Web of Science ®Google Scholar
• Petrykiv S, Sjöström CD, Greasley PJ, et al. Differential effects of dapagliflozin on cardiovascular risk factors at varying degrees of renal function. Clin J Am Soc Nephrol. 2017;12(5):751–759. doi: 10.2215/CJN.10180916.
   PubMed Web of Science ®Google Scholar
• Heerspink HJ, Desai M, Jardine M, et al. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28(1):368–375. doi: 10.1681/ASN.2016030278.
   PubMed Web of Science ®Google Scholar
• DeFronzo RA, Norton L, Abdul-Ghani M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat Rev Nephrol. 2017;13(1):11–26. doi: 10.1038/nrneph.2016.170.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Rev Esp Cardiol . 2021;74(9):790–799. doi: 10.1016/j.recesp.2021.06.016.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–1558. doi: 10.1002/sim.1186.
   PubMed Web of Science ®Google Scholar
• Ronksley PE, Brien SE, Turner BJ, et al. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ. 2011;342:d671–d671. doi: 10.1136/bmj.d671.
   PubMed Web of Science ®Google Scholar
• Solomon SD, Mcmurray JJV, Claggett B, et al. Dapagliflozin in heart failure with mildly reduced or preserved ejection fraction. N Engl J Med. 2022;387(12):1089–1098. doi: 10.1056/NEJMoa2206286.
   PubMed Web of Science ®Google Scholar
• Mcmurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019;381(21):1995–2008. doi: 10.1056/NEJMoa1911303.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Ferrannini E, Umpierrez GE, et al. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment. Diabetes Obes Metab. 2021;23(12):2632–2642. doi: 10.1111/dom.14513.
   PubMed Web of Science ®Google Scholar
• Allegretti AS, Zhang WB, Zhou WJ, et al. Safety and effectiveness of bexagliflozin in patients with type 2 diabetes mellitus and stage 3a/3b CKD. Am J Kidney Dis. 2019;74(3):328–337. doi: 10.1053/j.ajkd.2019.03.417.
   PubMed Web of Science ®Google Scholar
• Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–657. doi: 10.1056/NEJMoa1611925.
   PubMed Web of Science ®Google Scholar
• Herrington WG, Staplin N, Green JB, et al. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388(2):117–127. doi: 10.1056/NEJMoa2204233.
   PubMed Web of Science ®Google Scholar
• Anker SD, Butler J, Filippatos G, et al. Empagliflozin in heart failure with a preserved ejection fraction. N Engl J Med. 2021;385(16):1451–1461. doi: 10.1056/NEJMoa2107038.
   PubMed Web of Science ®Google Scholar
• Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383(15):1413–1424. doi: 10.1056/NEJMoa2022190.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Pratley R, Dagogo-Jack S, et al. Cardiovascular outcomes with ertugliflozin in type 2 diabetes. N Engl J Med. 2020;383(15):1425–1435. doi: 10.1056/NEJMoa2004967.
   PubMed Web of Science ®Google Scholar
• Lin DSH, Lee JK, Chen WJ. Clinical adverse events associated with sodium-glucose cotransporter 2 inhibitors: a meta-analysis involving 10 randomized clinical trials and 71 553 individuals. J Clin Endocrinol Metab. 2021;106(7):2133–2145. doi: 10.1210/clinem/dgab274.
   PubMed Web of Science ®Google Scholar
• D'Andrea E, Wexler DJ, Kim SC, et al. Comparing effectiveness and safety of SGLT2 inhibitors vs DPP-4 inhibitors in patients with type 2 diabetes and varying baseline HbA1c levels. JAMA Intern Med. 2023;183(3):242–254. doi: 10.1001/jamainternmed.2022.6664.
   PubMed Web of Science ®Google Scholar
• Baviera M, Foresta A, Colacioppo P, et al. Effectiveness and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in type 2 diabetes: an Italian cohort study. Cardiovasc Diabetol. 2022;21(1):162. doi: 10.1186/s12933-022-01572-y.
   PubMed Web of Science ®Google Scholar
• Lunati ME, Cimino V, Gandolfi A, et al. SGLT2-inhibitors are effective and safe in the elderly: the SOLD study. Pharmacol Res. 2022;183:106396. doi: 10.1016/j.phrs.2022.106396.
   PubMed Web of Science ®Google Scholar
• Umpierrez G, Korytkowski M. Diabetic emergencies - ketoacidosis, hyperglycaemic hyperosmolar state and hypoglycaemia. Nat Rev Endocrinol. 2016;12(4):222–232. doi: 10.1038/nrendo.2016.15.
   PubMed Web of Science ®Google Scholar
• Dhatariya KK, Glaser NS, Codner E, et al. Diabetic ketoacidosis. Nat Rev Dis Primers. 2020;6(1):40. doi: 10.1038/s41572-020-0165-1.
   PubMed Web of Science ®Google Scholar
• Zinman B, Lachin JM, Inzucchi SE. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2016;374(11):1094. doi: 10.1056/NEJMc1600827.
   PubMed Web of Science ®Google Scholar
• Solini A, Sebastiani G, Nigi L, et al. Dapagliflozin modulates glucagon secretion in an SGLT2-independent manner in murine alpha cells. Diabetes Metab. 2017;43(6):512–520. doi: 10.1016/j.diabet.2017.04.002.
   PubMed Web of Science ®Google Scholar
• Merovci A, Solis-Herrera C, Daniele G, et al. Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. J Clin Invest. 2014;124(2):509–514. doi: 10.1172/JCI70704.
   PubMed Web of Science ®Google Scholar
• Perry RJ, Rabin-Court A, Song JD, et al. Dehydration and insulinopenia are necessary and sufficient for euglycemic ketoacidosis in SGLT2 inhibitor-treated rats. Nat Commun. 2019;10(1):548. doi: 10.1038/s41467-019-08466-w.
   PubMed Web of Science ®Google Scholar
• Goldenberg RM, Berard LD, Cheng AYY, et al. SGLT2 inhibitor-associated diabetic ketoacidosis: clinical review and recommendations for prevention and diagnosis. Clin Ther. 2016;38(12):2654–2664. e1. doi: 10.1016/j.clinthera.2016.11.002.
   PubMed Web of Science ®Google Scholar
• Matthaei S, Bowering K, Rohwedder K, et al. Dapagliflozin improves glycemic control and reduces body weight as add-on therapy to metformin plus sulfonylurea: a 24-week randomized, double-blind clinical trial. Diabetes Care. 2015;38(3):365–372. doi: 10.2337/dc14-0666.
   PubMed Web of Science ®Google Scholar
• Erondu N, Desai M, Ways K, et al. Diabetic ketoacidosis and related events in the canagliflozin type 2 diabetes clinical program. Diabetes Care. 2015;38(9):1680–1686. doi: 10.2337/dc15-1251.
   PubMed Web of Science ®Google Scholar
• Menne J, Dumann E, Haller H, et al. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: a systematic review and meta-analysis. PLoS Med. 2019;16(12):e1002983. doi: 10.1371/journal.pmed.1002983.
   PubMed Web of Science ®Google Scholar
• Fralick M, Kim SC, Schneeweiss S, et al. Risk of amputation with canagliflozin across categories of age and cardiovascular risk in three US nationwide databases: cohort study. BMJ. 2020;370:m2812. doi: 10.1136/bmj.m2812.
   PubMed Web of Science ®Google Scholar
• Ueda P, Svanstrom H, Melbye M, et al. Sodium glucose cotransporter 2 inhibitors and risk of serious adverse events: nationwide register based cohort study. BMJ. 2018;363:k4365. doi: 10.1136/bmj.k4365.
   PubMed Web of Science ®Google Scholar
• Potier L, Mohammedi K, Velho G, et al. SGLT2 inhibitors and lower limb complications: the diuretic-induced hypovolemia hypothesis. Cardiovasc Diabetol. 2021;20(1):107. doi: 10.1186/s12933-021-01301-x.
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Szarek M, Pitt B, et al. Sotagliflozin in patients with diabetes and chronic kidney disease. N Engl J Med. 2021;384(2):129–139. doi: 10.1056/NEJMoa2030186.
   PubMed Web of Science ®Google Scholar